

ASX Announcement

Mary Harney appointed Non-Executive Director of Race

- Former CEO, Royal Australasian College of Surgeons, Mary Harney appointed Non-Executive Director of Race
 - Ms Harney brings deep understanding of academic and applied life science research, in addition to biopharmaceutical regulatory affairs and commercialisation.
 - Appointment adds an additional independent director to the Race Board, so balancing current executive directorships
-

8 February 2021 – Race Oncology Limited (**Race** or the **Company**) (ASX: RAC) is pleased to announce that Ms Mary Harney has been appointed Non-Executive Director.

An accomplished NED and Chief Executive, Ms Harney brings deep understanding of academic and applied life science research, in addition to biopharmaceutical regulatory affairs and commercialisation capability.

Ms Harney is the director of specialist consulting firm - Mary Harney Advisory - providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. She currently also serves as Chairman of private Australian biotech, CTxONE Pty Ltd – a cancer drug discovery and development company pursuing novel epigenetic and immuno-oncology programs.

She was formerly the CEO of Royal Australasian College of Surgeons; CEO of Gardiner Research Foundation; COO and Director of Office of Cancer Research for Peter MacCallum Hospital and COO of Cerylid Biosciences. Other former roles were with CSL, Amrad, BIOPROPERTIES and Royal Melbourne Hospital.

Race Chairman, Dr John Cullity commented: *“Mary brings an exceptional pedigree to the Race Board and we welcome her appointment. She is a credentialed company director with strong commercial experience, based on multiple years developing assets in oncology and the broader healthcare landscape. Mary joins me as an independent director, so balancing Phil and Daniel’s executive directorships.”*

Ms Mary Harney commented, *“I’m joining the Board at a key moment in the development of both the company, and Bisantrone. Race holds unique and commercially powerful ingredients – Bisantrone with a new development strategy which highlights multiple value points; new potential solutions to long-standing patient problems and a team of critical-thinkers. I am humbled to be invited to bring my network and skillset to the table, from a long career in oncology, health and corporate governance.”*

Ms Harney holds a Bachelor of Science from Monash University, a Bachelor of Arts from the University of Melbourne and is a fellow of the Australian Institute of Company Directors.

Ms Harney is a Fellow of the Institute of Managers, Member of the Australian Institute of Company Directors (AICD) and completed the AICD course in 2000. In 2017, she completed 'Strategy in the Age of Digital Disruption' at INSEAD Business School (Global #1 Business School). Her appointment is effective immediately.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene.

Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Bisantrene. See more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au